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Abstract
Objective and design To develop a model of the inflam-
matory component of non-infectious sore throat using tonic
stimulation and quantification of inflammatory mediators
in pharyngeal lavage fluid.
Material or subjects Forty-five healthy volunteers.
Treatment Cold dry air.
Method Tonic stimulation of the pharynx was achieved
using a constant stream of cold dry air to the back of the
throat. Following optimization of stimulation conditions
(phase 1), pharyngeal pain, irritation, and swallowing dis-
comfort were assessed using visual analog scales, and the
concentration of inflammatory markers were measured in
pharyngeal lavage fluid (phase 2).
Results Optimum conditions for tonic pharyngeal stimu-
lation were cold dry air at 12 C, relative humidity 20 %, at
a flow rate of 12 L/min for 15 min. Analysis of pharyngeal
lavage fluid collected 5 min after stimulation showed sig-
nificant increases in prostaglandin E2 (P = 0.018),
thromboxane B2 (P \ 0.001), and substance P (P \ 0.001),
but no increase in peptidoleukotriene. When the stimulus
was removed, the level of inflammatory markers in pha-
ryngeal lavage fluid returned to baseline by 30 min post-
stimulation. These objective measures mirrored subjective
pain ratings.
Conclusions Tonic stimulation of the pharyngeal mucosa
with cold dry air causes pain and an increase of inflam-
matory mediators which are reversible.
Keywords Cold dry air  Experimental model 
Inflammation  Sore throat  Pharyngitis
Introduction
Pharyngitis (sore throat) can be caused by infectious agents
(viruses, bacteria, and fungi) or physico-chemical (such as
smoking, snoring, shouting, tracheal intubation, medica-
tions, or concomitant illness) or environmental (including
indoor and outdoor air pollutants, temperature and
humidity, and hazardous or occupational irritants) factors
[1]. However, the underlying pathophysiology of non-
infectious sore throat is not well understood, and experi-
mental models with defined conditions and objective
endpoints are needed to study the mechanisms and evaluate
treatment strategies [1].
Many of the currently available models are not specific
for sore throat or use subjective endpoints. There are sev-
eral models for the study of non-allergic rhinitis, but they
mainly induce nasal symptoms—examples include intra-
nasal challenge with histamine [2], capsaicin [3], or
methacholine [4], as reviewed previously [5]. While nasal
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provocation with bradykinin induces sore throat, it also
induces rhinitis [6]. The rating of sore throat pain [7, 8] is
specific for sore throat, but the endpoint is subjective. In
preclinical settings, there is no animal model available to
test drugs for the treatment of sore throat.
Nasal stimulation with cold dry air is an established
model for rhinitis [5], and may be a suitable model for the
inflammatory component of some etiologies of non-infec-
tious sore throat when applied to the pharynx. When
introduced to the nasal cavity of volunteers, a stream of air
induces pain, the intensity of which varies depending on
humidity and temperature [9], and potentially air flow rate.
Previous work in our laboratory used cold dry air (22 C,
20 % relative humidity, 8 L/min) to experimentally induce
rhinitis in healthy volunteers [10]. The assessment of
inflammatory mediators in nasal lavage fluid provides an
objective measure of inflammation [11] and quantifies the
response to nasal cold dry air provocation [10]. Pain induced
by nasal application of cold dry air has been used to assess
the anti-inflammatory and analgesic properties of acetami-
nophen, ibuprofen, ketoprofen, and azapropazone [12–15].
Pharyngeal lavage has been used to investigate mucosal
inflammation in the pharynx of patients with sleep-related
disordered breathing [16]. In the current study, we devel-
oped a model of pharyngeal inflammation using local
application of cold dry air, with quantification of inflam-
matory mediators in pharyngeal lavage fluid.
Materials and methods
The study was approved by the University of Erlangen-
Nuremberg’s institutional review board, and was con-
ducted in agreement with the Declaration of Helsinki
(Tokyo amendment). Parts of the data are published in a
thesis [17].
Subjects
A total of 45 healthy volunteers participated, with a mean
age of 25.2 ± 1.9 years (range 22–34 years), including 23
males and 22 females. Five subjects participated in pre-
liminary experiments. Subsequently, 20 subjects
participated in phase 1 and 20 subjects participated in
phase 2. They were recruited at the Department of
Experimental and Clinical Pharmacology and Toxicology,
University of Erlangen-Nuremberg, Germany. The study
was conducted between October 1998 and June 2000, and
prior to commencement, written informed consent was
obtained from all subjects. The participants received 100
DM (about 50 Euro) for each experimental session.
Inclusion criteria included volunteers who were physi-
cally and mentally healthy, aged 18–45 years, and of
normal body weight (Broca Index ±25 %). Excluded were
those subjects with evidence or suspicion of any clinical
abnormality, any acute or chronic infection or allergy
requiring therapy, those who were taking concomitant
medication (except contraceptives) or who had taken
medication within the previous 4 weeks, and those with
relevant loss of blood within the last month. Smokers
(more than 15 cigarettes/day) were excluded, as were
people dependant on drugs or ingesting more than 60 g
alcohol/day, and those with any diet (including vegetarian)
or lifestyle that would interfere with the study. Also
excluded were people with known or suspected non-com-
pliance, pregnant or lactating women, and those with actual
or anamnestic bronchial asthma.
All subjects underwent pre-study screening to confirm
their health, including a general medical examination,
measurement of vital signs, and 12-lead electrocardiogram.
In a training session prior to the study, the subjects were
familiarized with the experimental procedures and with
velopharyngeal closure, a breathing technique that avoids
respiratory flow within the nasal cavity during stimulation
[18]. This ensures the delivery of the stimulus is indepen-
dent of breathing through the nose which could otherwise
influence its intensity and hence the subject’s response.
Tonic stimulation of the pharynx
Stimulation of the pharynx was achieved using a constant
stream of cold dry air to the back of the throat (Fig. 1). The
optimum conditions for this were established in phase 1.
Low relative humidity (20 %) was achieved by passing the
airstream through a bottle filled with silica gel. For ther-
mostabilization, the bottle and tubing were located in a
thermostat. All materials were made of glass or Teflon.
During all studies, the subjects were comfortably seated
in an air-conditioned room with white noise used to pro-
vide acoustic shielding. Subjects fasted for at least 6 h
Fig. 1 Schematic diagram showing the apparatus used to apply cold
dry air to the pharynx of volunteers
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before each experiment. They brushed their teeth 2 h
before each experiment with the standard toothbrush and
toothpaste provided. Thereafter, no smoking and only
water was allowed. Subjects cleaned their mouth with
water 15 min before each session.
In order to stabilize vigilance during the experiments,
the subjects were required to perform a tracking task on a
video screen [19]. Using a joystick, they had to keep a
small square within a randomly moving larger square. By
measuring this ‘tracking performance’ it was possible to
monitor the vigilance of the subjects.
Phase 1: optimization of tonic pharyngeal stimulation
A range of conditions for stimulation of the pharynx were
investigated in pilot experiments in five subjects. Optimum
conditions for stimulation of the pharynx were identified in
phase 1 of the study in 20 subjects: at a relative humidity of
20 %, different combinations of air flow, temperature, and
duration of stimulus were investigated (Table 1). Pain
intensity and aversion were assessed by a visual analog
scale (VAS) throughout stimulation. Each subject under-
went 15 sessions (randomized, single blind) in total
(Table 1), with one session per day and at least 2 days
between each session.
Phase 2: effect of tonic pharyngeal stimulation
on inflammatory markers and pain
In phase 2, the effect of the optimum cold dry air condi-
tions determined in phase 1 (12 C, relative humidity
20 %, at 12 L/min for 15 min) on pharyngeal pain, irrita-
tion, and swallowing discomfort (VAS) and concentration
of inflammatory markers in pharyngeal lavage fluid was
assessed in 20 subjects. Each subject underwent one ses-
sion of tonic pharyngeal stimulation on each of 2 days.
Assessment of subject’s perception of pain
and discomfort
During stimulation, every 60 s during the application of the
air flow to the pharynx, the subjects rated the intensity of
and aversion to pain on a VAS displayed on a computer
screen [19]. The pain intensity scale ran from 0 (no pain) to
100 (maximal imaginable pain) and the aversion scale ran
from 0 (no aversion) to 100 (maximal aversion). The pain
intensity scale was the primary indicator, whilst the aver-
sion scale was used to check for non-pain adverse events or
discomfort.
After stimulation, throat pain, throat irritation, and dis-
comfort while swallowing were assessed every 10 min for
80–90 min post-stimulation. The VAS for these ran from 0
(no pain) to 100 (maximal imaginable pain), from 0 (no
irritation) to 100 (maximal irritation), and from 0 (no
swallowing discomfort) to 100 (maximal swallowing
discomfort).
Pharyngeal lavage technique
Pharyngeal lavage was performed immediately before (at
0 min), and at 5 and 30 min after pharyngeal stimulation.
The subjects were asked to gargle with 10 mL of warmed
(37 C) Ringer’s solution (pH 5–7) for 10 s. After col-
lecting the lavage fluid it was immediately centrifuged
(10 min, 1,700 rpm, 4 C) to separate the cell pellet, then
frozen at -80 C until further analysis.
Measurement of inflammatory mediators
Pilot experiments in five subjects determined if inflam-
matory mediators could be measured in pharyngeal lavage
fluid. The concentrations of inflammatory mediators
[prostaglandin E2 (PGE2), peptidoleukotriene (PLT),
thromboxane B2 (TXB), and substance P (SP)] in pharyn-
geal lavage fluid were measured by enzyme-linked
immunosorbent assay (ELISA) (Cayman Chemical Com-
pany, Ann Arbor, MI, USA). These mediators were
selected following their responsiveness to nasal stimulation
with cold dry air [10], and the presence of substance P in
sensory nerve fibres of the upper respiratory tract [20].
After defrosting, analysis of TXB and SP was conducted
using undiluted samples, whilst those for PGE2 and PLT
were diluted 1:10 with Ringer Lactate solution (Braun,
Melsungen, Germany). The intensity of colour change was
Table 1 The conditions which were investigated during phase 1 to







1 12 12 15
2 12 12 5
3 12 12 10
4 12 12 20
5 12 12 25
6 6 12 15
7 8 12 15
8 10 12 15
9 14 12 15
10 12 4 15
11 12 6 15
12 12 8 15
13 12 10 15
14 12 15 15
15 12 18 15
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determined spectrophotometrically (microplate reader
MR2100, Firma Dynex Technologies, Du¨sseldorf, Ger-
many). Results outside the validated range were excluded
and treated as missing data.
Statistical analyses
Outcome measures were subjective ratings of pain intensity
and aversion during stimulation, subjective ratings of pain,
irritation, and swallowing discomfort after stimulation, and
pre- and post-stimulation concentrations of inflammatory
mediators (PGE2, PLT, TXB, and SP) in lavage fluid.
All statistical analyses were conducted using IBM SPSS
Statistics 21 (Chicago, IL, USA). Descriptive analyses
included calculation of mean, range, standard deviation, and
standard error. Repeated measures ANOVA was used for
inflammatory mediators in order to detect stimulation and
recovery effects over time. Student’s t tests were used as post
hoc tests, adjusting each P value according to Bonferroni.
Spearman rank correlation coefficient was used for analysis
of correlations between increases of different mediators and
pain ratings after cold dry air stimulation compared with
baseline. Data are presented as means with 95 % confidence
intervals (CI). P \ 0.05 was considered significant.
Results
Phase 1: optimization of tonic pharyngeal stimulation
When combinations of stimulation parameters (Table 1)
were investigated in phase 1 (n = 20) it was clear that the
greatest intensity of pharyngeal pain was achieved using
12 L/min, at 12 C, for 15 min (condition 1 in Table 1;
Fig. 2a). Warming the air to 18 C considerably reduced
the pain intensity (condition 15 in Table 1; Fig. 2a).
Cooling the airflow to below 12 C (conditions 10–13) or
increasing the duration of the stimulus (conditions 4–5) did
not further increase the pain intensity (Fig. 2a). Ratings of
aversion throughout generally followed the same trends
(Fig. 2b). The optimum conditions for tonic pharyngeal
stimulation were therefore determined to be 12 L/min at
12 C for 15 min.
Phase 2: effect of tonic pharyngeal stimulation
on inflammatory markers and pain
In phase 2 (n = 20), there was a significant change in all
inflammatory mediators over time (PGE2: df = 2, F = 5.7,
P = 0.005; TXB: df = 2, F = 8.5, P \ 0.001; SP: df = 2,
F = 18.5, P \ 0.001, PLT: df = 2, F = 4.4, P = 0.028).
Post hoc analysis of pharyngeal lavage fluid collected
5 min after tonic pharyngeal stimulation showed significant
increases in PGE2 (P = 0.018), TXB (P \ 0.001), and SP
(P \ 0.001) compared with baseline (Fig. 3). When the
stimulus was removed, the level of inflammatory markers
in pharyngeal lavage fluid returned to baseline by 30 min
post-stimulation (Fig. 3). There was no significant increase
in PLT upon tonic pharyngeal stimulation (change from
baseline 161 pg/mL (95 % CI 52–270 pg/mL) and 105 pg/
mL (95 % CI 10–200 pg/mL) for first and second time
point after stimulation, n = 14).
The phase 2 VAS results (n = 20) show the pharyngeal
pain (Fig. 4a) and stimulus aversion (Fig. 4d, supplement)
during tonic pharyngeal stimulation (12 L/min at 12 C for
15 min), which increases progressively from the onset of
the stimulus and throughout its duration. After removal of
the stimulus, irritation (Fig. 4b) and swallowing difficulty
(Fig. 4c) peak and then progressively improve over the
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Fig. 2 Pharyngeal pain intensity (a) and aversion (b) (mean 95 %
confidence interval), measured on visual analog scales (VAS), during
phase 1 tonic pharyngeal stimulation with cold dry air varying in flow
rate, temperature, and duration of stimulus. For details of the air flow
characteristics for each of the 15 experiments see Table 1
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Correlation analysis showed that the increased pain
ratings during cold dry air stimulation and decreased rat-
ings thereafter coincided with changes in mediator release.
This was significant for TXB (P = 0.042; r = 0.231) and
SP (P = 0.034; r = 0.237), but was not significant for PLT
and PGE2.
Discussion
This study shows that tonic stimulation of the pharyngeal
mucosa with cold dry air causes pain, irritation, and dis-
comfort whilst swallowing and an increase of inflammatory
mediators, which is reversible. This is the first sore throat
model that is both specific to the pharynx and includes an
objective endpoint (pharyngeal inflammatory markers).
Other currently available techniques [7, 8] do not routinely
measure inflammatory mediators and rely on assessment of
the physical appearance of inflammation.
The properties of an ideal pain model have previously
been described [21]. An ideal stimulus should exhibit
minimal neurohistologic variation between individuals,
should be measureable, closely associated with the changes
which produce inflammation, provoke minimal tissue
damage, show a relation to pain intensity, provide infor-
mation about discrimination between stimuli, result in
repeatable stimulation without temporal interaction, be
applied easily, allow a quantifiable determination of the
quality of inflammation, be sensitive to agents of low
analgesic power, show dose-related effects of anti-inflam-
matory drugs, and be applicable for both man and animal
[10]. The current sore throat pain model satisfies many of
these criteria, although its sensitivity and dose-response to
anti-inflammatory agents was not tested.
The optimum conditions for pharyngeal stimulation were
confirmed to be cold dry air at 12 L/min, 20 % relative
humidity and 12 C, with a 15-min stimulus duration. These
conditions maximized the subjective pharyngeal pain repor-
ted by the volunteers, and hence maximized the sensitivity of
the model. The conditions required for optimum tonic stim-
ulation of the pharynx are somewhat harsher than those
employed for the nasal cavity (22 C, 20 % relative
humidity, 8 L/min) [10], and this may be due to the relative
sensitivity of the mucosa at these locations. There may be
differences in innervation and/or neuropeptide release [20],
and the clearance of inflammatory mediators and neuropep-
tides on the pharyngeal mucosa may also be enhanced by
saliva production, which is not the case in the nasal cavity.
The single-layer respiratory epithelium (pseudostratified)
changes to a multiple-layer epithelium in the lower pharynx,
and this could also influence sensitivity.
The increase in inflammatory markers in pharyngeal















Fig. 3 Change (mean 95 % confidence interval, n = 20) in a pros-
taglandin E2, b thromboxane B2, c substance P in pharyngeal lavage
fluid of healthy volunteers after tonic pharyngeal stimulation (the grey
shaded area) with cold dry air (12 C, 20 % humidity at 12 L/min for
15 min). Results are the means of two tests. Student’s t test was used
with Bonferroni-adjusted P values shown
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provides an objective measure that mirrors the subjective
pain ratings. Both pain and inflammatory markers increased
upon stimulation then returned to baseline shortly after-
wards. The timing of the peak of inflammatory markers
coincided with the pain measures. However, inflammatory
mediators returned to baseline more quickly (at about
30 min after the stimulus was removed) compared with pain
measures (at about 80–90 min after the stimulus was
removed). In this regard, we could not exclude any dilution
effects caused by repetitive lavage sampling, which will be
pronounced during post-stimulation periods. Our analysis
reflected this time shift as only SP and TXB but not PGE2 or
PLT release correlated with changes in pain ratings. How-
ever, a moderate correlation is typical for subjective ratings
and was also observed in a previous study, following stim-
ulation of the nasal mucosa with cold dry air [22].
In the current study, PGE2, TXB, and SP levels in
pharyngeal lavage fluid were significantly increased by
cold dry air; but there was no significant effect on PLT. In
contrast, a previous study found significant increases in
PLT in nasal lavage fluid when cold dry air was applied to
the nasal cavity, although increases in PGE2 and TXB
failed to reach significance [10]. The differences between
studies may be due to variability in the data or missing
values. The data are currently insufficient to determine if
the differences in mediator responses (within the current
study, and between studies) are due to anatomical location,
stimulus characteristics, or other methodological variation.
Previous data on pharyngeal lavage are not informative as
they are limited to inflammatory cell counts rather than
inflammatory mediators [16]. The significant increases in
pharyngeal PGE2, TXB, and SP in the current study show
that these mediators are implicated in the inflammation
induced by cold dry air. Whereas SP is known to be
involved in nociception and the development of hyperal-
gesia, PGE2 and TXB may have contrary physiological
effects (for example, bronchial relaxation versus constric-
tion). We included these mediators because PGE2 and TXB
may be used to quantify the effect of selective and unse-
lective cyclooxygenase inhibitors [23]. As we measured the
acute release of these mediators (during the 15-min stim-
ulation period), there is limited information about lipid
mediator production which takes 30 min or longer. How-
ever, since we observed rapid recovery of pain and
mediator release, the stimulation could potentially be
repeated several times per day in order to obtain longer-
term effects on inflammatory mediator induction or regu-
lation. Other lipid mediators are likely to be involved but
were not analyzed in the current study. Regulators of
pharyngeal inflammation (pro-inflammatory and anti-
inflammatory) warrant further study, and the current model
may provide a tool for this. From human studies of nasal






























































Fig. 4 Change (mean 95 % confidence interval, n = 20) in pharyn-
geal pain intensity (a), irritation (b) and swallowing difficulty (c) of
healthy volunteers, measured on visual analog scale (VAS), during
(the grey shaded area) and after tonic pharyngeal stimulation with
cold dry air (12 C, 20 % humidity at 12 L/min for 15 min). Results
are the means of two tests. VAS for pharyngeal irritation and
swallowing difficulty were not recorded during the stimulation period
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generation of leukotrienes and kinins; although only in
predisposed subjects with rhinitis [22, 24].
The lack of PLT response in the current study may be due
to a higher degradation of PLT or greater differences in
local production/secretion of PLT. The ELISA kit used for
analysis of PLT in the current study detected leukotriene
(LT) C4, LTD4 and the degraded metabolite LTE4. Since the
kit provides a high specificity for LTC4 and LTD4 (100 %)
and a lower specificity for LTE4 (below 70 %), differences
in degradation state may contribute to the PLT data vari-
ability observed in the current study. The degradation of
LTE4 to undetectable metabolites is incomplete in bron-
choalveolar samples, but the degradation time response is
currently unknown in samples containing saliva. Method-
ological differences between the current study and the nasal
lavage study [10] include different sample volumes (10 vs.
6 mL, respectively), which could affect sensitivity.
In summary, the cold dry air model presented here
provides a well-controlled, easily-applied technique for
inducing reversible sore throat pain that is specific to the
pharynx and can be measured objectively. This model will
be of benefit for the future development of analgesics for
alleviating non-infectious sore throat of some etiologies
with an inflammatory component, the investigation of
environmental causes of sore throat [1] including allergic
and nonallergic states in environmental medicine, as well
as toxicology exposure studies with defined stimulus con-
ditions in addition to cold dry air.
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